High efficacy of Resistance-guided retreatment of HCVpatients failing NS5A inhibitors in real world

According to the World Health Organization, there are approximately 71 million people infected with Hepatitis C virus (HCV) worldwide and 1.75 million people are diagnosed each year[1]. In the absence of antiviral treatment, HCV leads to cirrhosis, hepatocellular carcinoma (HCC), liver failure and death[2]. Treatment with direct-acting antivirals (DAA) is highly efficacious and it has limited side effects[3]. Current DAA combinations that are recommended as first-line treatment of HCV-infected patients by the AASLD-IDSA[4] and EASL guidelines[5] allow achieving sustained virological response (SVR) rates>90% for all HCV genotypes.

Source: Journal of Hepatology - July 3, 2019 Category: Gastroenterology Authors: Ana Bel én Pérez, Natalia Chueca, Miguel García-Deltoro, Ana María Martínez-Sapiña, María Magdalena Lara-Pérez, Silvia García-Bujalance, Teresa Aldámiz-Echevarría, Francisco Jesús Vera-Méndez, Juan Antonio Pineda, Marta Casado, Juan Manuel Pa Source Type: research